Serum α-fetoproteinmeasuredwere measured by radioimmunoassay in patpatients with biopsy-proved nonneoplastic hepatic disorders; 22% had values greater than 40 ng/ml, whereas only 1 of 350 patients with nonhepatic benign diseases had a value greater than this. Levels exceeded 40 ng/ml in more than 30% of patients with various types of hepatitis, and in 0% to 15% with inactive postnecrotic cirrhosis, primary biliary cirrhosis, biliary tract ob-astruction, and alcoholic liver disease. Values greater than 500 ng/ml were observed solely in viral subacute hepatic necrosis. Only one patient had a level exceeding 3,000 ng/ml, the concentration at which α-fetoprotein is detectable by agar-gel diffusion. Of 75 patients with hepatoma, serum α-fetoprotein levels exceeded 40 ng/ml in 69%, and exceeded 3,000 ng/ml in 48%. These studies indicate that serum protein levels exlevels are elevated in severalenonneoplastic hepatic disorders when a sensitive assay is used; this phenomenon may reflect hepatic regeneration.serum α-fetoproteinlevated in several nonneoplastic hepatic disorders when a sensitive assay is used; this s used; this ph reflect hepatic regeneration.
(JAMA ation. (JAMA 233
Bloomer JR, Waldmann TA, McIntire KR, Klatskin G. α-Fetoprotein in Nonneoplastic Hepatic Disorders. JAMA. 1975;233(1):38-41. doi:10.1001/jama.1975.03260010040018